Heterocyclic Compounds, 1-Ring
"Heterocyclic Compounds, 1-Ring" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.
Concept/Terms
Heterocyclic Compounds, 1-Ring- Heterocyclic Compounds, 1-Ring
- 1-Ring Heterocyclic Compounds
- Compounds, 1-Ring Heterocyclic
- Heterocyclic Compounds, 1 Ring
- Heterocyclic Cpds, 1-Ring
- 1-Ring Heterocyclic Cpds
- Cpds, 1-Ring Heterocyclic
- Heterocyclic Cpds, 1 Ring
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 1-Ring".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 1-Ring".
This graph shows the total number of publications written about "Heterocyclic Compounds, 1-Ring" by people in Harvard Catalyst Profiles by year, and whether "Heterocyclic Compounds, 1-Ring" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 1 | 1 | 2 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2007 | 1 | 2 | 3 |
2008 | 2 | 0 | 2 |
2010 | 1 | 3 | 4 |
2011 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2013 | 2 | 1 | 3 |
2014 | 1 | 1 | 2 |
2015 | 1 | 1 | 2 |
2016 | 0 | 1 | 1 |
2017 | 0 | 3 | 3 |
2018 | 3 | 0 | 3 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2022 | 2 | 1 | 3 |
2023 | 0 | 4 | 4 |
2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Heterocyclic Compounds, 1-Ring" by people in Profiles.
-
Automated radiolabeling and handling of 177 Lu- and 225 Ac-PSMA-617 using a robotic pipettor. J Labelled Comp Radiopharm. 2024 Mar; 67(3):111-115.
-
The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer. 2024 Feb 15; 154(4):692-700.
-
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 09; 64(9):1417-1423.
-
A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [68Ga]Ga-DOTA-TATE Derivatives. Bioconjug Chem. 2023 03 15; 34(3):549-561.
-
Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med. 2023 03; 64(3):349-350.
-
177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy. J Nucl Med Technol. 2022 09; 50(3):213-214.
-
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. Eur J Nucl Med Mol Imaging. 2022 09; 49(11):3627-3638.
-
Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. Nucl Med Commun. 2022 Apr 01; 43(4):369-377.
-
Catalytic Activation of Bioorthogonal Chemistry with Light (CABL) Enables Rapid, Spatiotemporally Controlled Labeling and No-Wash, Subcellular 3D-Patterning in Live Cells Using Long Wavelength Light. J Am Chem Soc. 2022 02 02; 144(4):1647-1662.
-
In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast Agent. Mol Imaging Biol. 2020 10; 22(5):1333-1341.